Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

umes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K"), most recent quarterly report on Form 10-Q filed with the SEC on August 8, 2012 (the "Form 10-Q"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; (vi) risks related to our ability to successfully launch and commercialize Esbriet in the EU and Canada, including successfully establishing a commercial operation in the EU and Canada and receiving favorable governmental pricing and reimbursement approvals in each EU country and
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune To Release Third Quarter Financial Results On November 7
2. InterMune To Present At JMP Securities Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune to Present at J. P. Morgan Healthcare Conference
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
8. Patient Safety Technologies Reports Third Quarter 2012 Results
9. PDI Reports 2012 Third Quarter Financial Results
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 News Facts ... India devoted to genome-based research for human health ... is taking a bite out of oral cancer with ... in India with the help of ... DataDirect Networks (DDN). , To fuel its cutting-edge cancer ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of Smart Data ... the recent ‘Hype Cycle for Life Sciences 2014 ’ ... key insights pertaining to the benefits in the knowledge ... Shanler and Stephen Davies, “The use of these systems ... scientific stakeholders, and support collaboration and innovation strategies as ...
(Date:9/23/2014)... Austin, TX (PRWEB) September 23, 2014 ... newest fertility clinic in South Austin, expanding a Central ... Austin and San Antonio. The satellite office for the ... and andrology options to the South Austin, Buda, Kyle ... bring effective and affordable fertility treatment directly to individuals ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ... the globe will convene at the Society ... to be held October 26-28 in Houston, ... research and practice in individualized integrative cancer ... researchers, nurses, psychologists, nutritionists, naturopaths, acupuncturists, and ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... and Play Capability of MyMedicalRecords Pro to ... Technology Experts Expected at HIMSS09LOS ANGELES, Feb. ... Bulletin Board: FVRL), which through its wholly-owned ... consumer-controlled Personal Health Records ("PHRs") ( www.mymedicalrecords.com ...
... Feb. 24 Particle Sciences Inc. today announced the ... from tissue hydration to the passivation of medical device ... series of patent-pending polymers that allow Particle Sciences to ... PS, Director of New Technologies.Particle Sciences has already used ...
Cached Biology Technology:Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 2MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 4MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 5Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System 2
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... New Rochelle, NY, September 22, 2014Cassava, also known as ... high yields in areas of Africa, Asia, and Latin ... With the availability of novel enzymes and processes designed ... then be used to produce sweeteners such as glucose, ... alternative to corn, as described in a Review article ...
(Date:9/22/2014)... manufacture their own "antifreeze" proteins to survive in ... side effect, researchers report: The protein-bound ice crystals ... when temperatures warm. , The finding is ... Academy of Sciences . , "We discovered what ... evolution of antifreeze proteins in Antarctic notothenioid fishes," ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... Honeybees can learn to avoid nectar containing natural plant ... scientists at Newcastle University have found. This means that ... such as almond or apple orchards bees struggle to find ... toxic nectar. With honeybee populations already under stress, the Newcastle ...
... NEW YORK CITY (December 20, 2010)The New York Stem ... member of the inaugural class of NYSCF-Robertson Investigators, who was ... the December 27, 2010 Person of the Year Issue. ... School, was lauded for his discovery of an innovative method ...
... environmental factors cause the diversityor numberof species to increase ... suggested that species diversity continues instead of entering into ... in the Caribbean not only supports the original theory ... resources all work together to achieve equilibrium; it builds ...
Cached Biology News:Bee challenged -- toxin-laden nectar poses problems for honeybees 2Time Magazine names Derrick Rossi to 2010 list of 'People Who Mattered' 2Research shows that environmental factors limit species diversity 2
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
NF kappa B Related Sampler Kit 10g each...
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
Biology Products: